228 Users Online
Muscle Pump Activator Market Segmented By Product type such as Wearable Device, Electro-stimulation Device used in Application for Indication includes Venous Thromboembolism, Wound Care, Kidney Transplantation
According to latest research by Persistent Market Research, the muscle pump activator market is still in its infancy, and thus expected to witness sluggish growth during the study period 2021-2031. Growing cases with associated risk venous thromboembolism (VTE) cases is expected to have a positive impact on the growth of the market.
Moreover, the market is further influenced by technological advancements to develop solutions to use across wide range of applications, hence providing lucrative opportunities for the market growth. However, lack of awareness of such technologies especially in emerging economies is expected to hinder the market growth.
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Venous thromboembolism (VTE) also known as deep vein thrombosis, occurs when blood clots the deep veins of legs, arms, gorin. Globally, VTE is one the leading cause of disability and death. Although exact number of individuals suffering from venous thromboembolism is not documented.
According to Centers of Disease Control and Prevention States, approximately each year 900,000 people could be affected (1or 2 per 1,000) in the U.S. Also, CDC states that approximately 60,000 -100,000 Americans die due to venous thromboembolism. Also, some 10-30% of the people will die within the initial one month of diagnosis.
Also, part from the disease burden, VTE also can lead to economic burden. Prolonged hospital stays and follow up care including recurrent VTE, can be heavy on pockets. For instance, In the U.S., the associated cost with the diagnosis and treatment costs US $ 15.5 billion per year, while in the U.K. VTE costs the National Health Services €640 million per year.
Also, the pacific regions are expected to witness the burden associated with the VTE, which is estimated to be at US $1.72 billion a year. Also, when loss of well-being such as disability and premature death are included, the can annual cost can rise to US $ 19.99 billion (Source: International Society on Thrombosis and Haemostasis).
Thus, high number of cases and economic burden associated with the VTE demands the enhance care which can improve the blood flow and mobility among the patients. Factors such as these are expected to drive the sales of the muscle pump activators.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionPrimarily used for treatment of venous thromboembolism (VTE), the muscle pump activators are now being studied for its use in other indications such as post-operative care during kidney transplantation. By using this device during post-operative care, it is anticipated to be effective by reducing the swelling in the lower-limb area.
Apart from expansion of use in kidney transplantation, the muscle pump activators proves beneficial in wound care therapy – treating chronic venous ulcers, reducing leg swelling (edema), reduces heavy legs and pain sensation, and also is effective in treating restless legs and night cramps. Thus, expanding use of the muscle pump activators in various indications are expected to drive the growth of the market during the forecast period of 2021—2031.
Growth in the U.S. and Canada is largely driven by the rise in number of patients associated with the venous thromboembolism (VTE). Moreover, various hospitals and healthcare facilities are focusing on running trials of these activators for post-surgical care during kidney transplantation. As per the research study conducted by Lawson Health Research Institutes (LHSC) in Ontario, Canada, they have found positive results from the patients using the geko wearable muscle pump.
Patients using these devices following kidney transplantation experienced shorter hospitals stays and reduced surgical site infection by 60%. Such positive results will help increase the adoption of muscle pump activators for innovative devices among hospitals and specialty clinics for improving quality for life specifically from the patients suffering from end stage renal disease. Additionally, well established distribution network (leading to better product availability) will positively drive the sales of muscle pump activators in the U.S. and Canada Market.
Sales Team
Client Partner
Followed by U.S. and the Canada, Europe is anticipated to be a second largest market for the muscle pump activators. Growing research and development activities, presence of key market players, venture capital investments, rising risk associated with growing number of VTE along with the growing economic burden is likely to augment the growth of the muscle pump activators in this regional segment.
Currently, only two players operates the muscle pump activator space, Ad Rem Technology (VENIOPLUS), and Sky Medical Technology Limited. These players offers muscle pump activators are primarily used to treat venous indications such as venous thromboembolism (VTE). Wound care, and pain management are some of the other indications where these devices can be used.
Muscle pump activators Mimicking body’s signals, these devices gently stimulates the common peroneal nerve, by activating the calf and muscle foot pumps, resulting into the improved blood circulation flow in the deep veins in the calf muscle which allows the complete mobility.
The ongoing advancements in research and development in this space, has allowed the use of these devices for use in other indications such as post-operative care after kidney transplantation. Majorly, these players are aiming to expand their presence across by via introducing new products and approvals and strengthing their existing, as well creating new distribution network. This strategic move will enable these players to expand their product offerings in the muscle pump activator market
For instance, in October 2019, Sky Medical Technology Ltd (U.K.) has received U.S. FDA approval for its muscle pump activator- geko, wearable device. These device will provide stimulation to calf muscles to prevent the risk of venous thromboembolism for non-surgical patients who are at risk of developing VTE.
By Product type
By Application/Indication
By Distribution Channel
By Region
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.
